TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A pooled, post-hoc analysis of two phase III trials found that postmenopausal women taking bedtime elinzanetant had slightly larger reductions in reported daytime sleepiness scores than those taking placebo. The exploratory findings do not establish that the drug improves alertness or rule out sleepiness for every patient; longer-term trial data are still expected.
A pooled post-hoc analysis of two phase III trials found that postmenopausal women taking the hot-flash drug elinzanetant at bedtime had slightly greater reductions in reported daytime sleepiness over 12 weeks than women taking placebo. The exploratory results, presented at the Menopause Society annual meeting, suggest the treatment did not add next-day sleepiness in the analyzed groups, a concern for medicines taken at night.
Researchers analyzed data from the OASIS I and OASIS II trials to examine whether bedtime dosing was associated with residual sleepiness the following day. The analysis used seven-day averages from a sleepiness scale, with scores ranging from 0 (not sleepy) to 4 (very sleepy). Investigators compared changes from baseline to week 12 in overall and morning, afternoon and evening scores.
Mean total sleepiness scores fell by 0.61 points with elinzanetant and 0.46 with placebo, a mean difference of -0.15 points. Morning scores fell by 0.66 and 0.39 points, respectively, for a difference of -0.27. Afternoon scores fell by 0.60 with the drug and 0.45 with placebo. Evening scores changed by -0.56 and -0.54, a difference of -0.02; the reported confidence interval for that comparison included no difference.
The researchers described the work as a post-hoc exploratory analysis, rather than a trial designed primarily to test daytime alertness. The report also noted that participants had moderate sleep disturbance on average at the start of the trials. At week 12, scores on a separate sleep-disturbance measure fell by 10.7 points in the elinzanetant group and 5.3 in the placebo group, with P<0.0001.
Daytime Alertness After Bedtime Dosing
Sleep disruption and hot flashes can occur together during menopause, and a medicine taken at night may raise questions about next-day functioning. These findings offer a preliminary answer for people considering elinzanetant: in the trial data examined, reported sleepiness did not rise relative to baseline, and scores fell somewhat more than with placebo.
The results are relevant but should be read narrowly. The score differences were modest, and this analysis does not show that elinzanetant makes people more alert, improves driving, or prevents sleepiness in every individual. It also does not replace a clinician’s assessment of side effects or suitability. The main established use described in the source is treatment of moderate to severe menopause-related vasomotor symptoms, not sleep disturbance.
menopause cooling pillow for night sweats
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
OASIS Trials and Menopause Symptoms
Elinzanetant, marketed as Lynkuet, is a nonhormonal dual neurokinin receptor antagonist that acts on NK1 and NK3 receptors. The OASIS I and II trials found reductions in the frequency and severity of hot flashes, along with improvements in sleep disturbance and menopause-related quality of life, according to the report. The U.S. Food and Drug Administration approved the medicine for moderate to severe vasomotor symptoms due to menopause.
Although it is taken at bedtime, elinzanetant is not indicated to treat sleep disturbance. The analysis was designed to assess daytime sleepiness and whether evening dosing appeared to carry over into the next day. A previous phase I study, as described in the report, also found no clinically relevant next-morning residual effect on simulated driving performance. That separate result does not establish real-world driving safety for every user.
“Patients treated with this medication, hoping to improve their vasomotor symptoms and sleep problems, can be reassured that they are unlikely to experience sleepiness the next day as an undesired, residual effect.”
— Claudio Soares, MD, PhD, of Queen’s University School of Medicine, speaking to MedPage Today
moisture wicking pajamas for menopause hot flashes
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Sleepiness Findings
The analysis was post hoc and exploratory, and the supplied report does not give the number of participants included in this specific sleepiness assessment or details of any adjustment for multiple comparisons. The confidence intervals provided were unadjusted. The results therefore indicate a pattern in the analyzed data, but do not establish a definitive effect on alertness or exclude side effects in particular patients.
It is also unclear from the report how the score changes translate into noticeable differences in everyday functioning. The findings cover the 12-week placebo-controlled period; they do not answer whether the same pattern persists over longer use. The report says additional OASIS III results are expected, but does not provide a presentation date.
portable handheld fan for hot flashes
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Longer-Term OASIS III Results
Soares and colleagues said data from the long-term OASIS III trial, which showed similar trends in sleepiness, will be presented later. Those results may add information about whether the pattern continues with longer treatment. Until they are available, the current finding remains a short-term analysis of reported scores from two earlier trials, rather than a stand-alone assessment of long-term daytime functioning.
cooling mattress pad for night sweats
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the analysis find about next-day sleepiness?
Across 12 weeks, average daytime sleepiness scores fell slightly more among participants taking elinzanetant than among those taking placebo. The analysis did not find a rise in reported sleepiness associated with bedtime dosing in the groups studied.
Was the study designed specifically to test daytime alertness?
No. It was a post-hoc exploratory analysis using data from OASIS I and II, not a primary trial designed to determine the drug’s effect on alertness.
Is elinzanetant approved as a sleep medicine?
No. The report says the medicine is approved for moderate to severe vasomotor symptoms due to menopause and is not indicated for sleep disturbance, even though it is recommended to be taken at bedtime.
Do the results prove the drug improves alertness or driving?
No. The score changes suggest no added next-day sleepiness in this analysis, but they do not prove improved alertness or real-world driving safety. A separate phase I study reported no clinically relevant residual effect on simulated driving performance.
What information is expected next?
The researchers said longer-term OASIS III data showing similar sleepiness trends will be presented at a later date. The report did not specify when.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
